Assessing the benefits of testing for breast cancer susceptibility genes: A decision analysis

Breast Disease

Volumn 10, Issue 1-2, 1998, Pages 115-125

  Berry, Donald A ^a   Parmigiani, Giovanni ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER SUSCEPTIBILITY; COST EFFECTIVENESS ANALYSIS; FAMILY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; INSURANCE; MEDICAL DECISION MAKING; ONCOGENE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; STATISTICAL MODEL;

EID: 0031945653     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1998-101-213     Document Type: Review

References (43)

1. Nelson NJ. Caution guides genetic testing for hereditary cancer genes. J Natl Cancer Inst 1996; 88(2):70-72.
2. Oncormed, Inc. Oncormed homepage. http://www.pslgroup.com/dg/oncormed.htm, August 1996.
3. Myriad Genetics, Inc. Myriad genetic homepage. http://www.myriad.com, October 1996.
4. Warmuth MA, Sutton LM, Winer EP. A review of hereditary breast cancer risk: from screening to risk factor modification. Am J Med 1997; 102:407-415.
5. Li FP; Fraumeni JF. Predictive testing for inherited mutations in cancer-susceptibility genes. J Clin Oncol 1990; 10(8):1203-1204.
6. Huggins M, Bloch M, Kanani S, et al. Ethical and legal dilemmas arising during predictive testing for adult-onset disease: the experience of Huntington disease. Am J Hum Genet 1990; 47:4-12.
7. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994; 271:785.
8. Hoskins KF, Stopfer JE, Calzone KA, et al. Asessment and counseling for women with a family history of breast cancer a guide for clinicians. JAMA 1995; 273:577-585.
9. National Action Plan on Breast Cancer; American Society of Clinical Oncology. Hereditary susceptibility to breast and ovarian cancer: An outline of the basic fundamental knowledge needed by all health care professionals. http://www.napbc.org/napbc/hsedcurr.htm, February 1997.
10. Struewing JP, Lerman C, Kase RG, et al. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 1995; 4:169-173.
11. Meissen GJ, Mastromauro CA, Kiely DK, et al. Understanding the decision to take the predictive test for huntington disease. Am J Med Genet 1991; 39(4):404-410.
12. Schwartz M, Lerman C, Daly M, et al. Utilization of ovarian cancer screening by women at increased risk. Cancer Epidemiol Biomarkers Prev 1995; 4(3):269-273.
13. Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet 1992; 50:476-482.
14. Wiggins S, Whyte P, Huggins M, et al. The psychological consequences of predictive testing for Huntington's disease. Canadian collaborative study of predictive testing. N Engl J Med 1992; 327(20):1401-1405.
15. Bloch M, Adam S, Fuller A, et al. Diagnosis of Huntington disease: a model for the stages of psychological response based on experience of a predictive testing program. Am J Med Genet 1993; 47(3):368-374.
16. Berry DA. Statistics: A Bayesian perspective. Belmont, Duxbury, 1996.
17. Bloch M, Fahy M, Fox S, Hayden MR. Predictive testing for Huntington disease: Ii. demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet 1989; 32:217-224.
18. Evans AM, Love RR, Meyerowitz BE, Leventhal H, Nerenz DR. Factors associated with active participation in a cancer prevention clinic. Prev Med 1985; 14(3):358-371.
19. Stefanek ME, Wilcox P. First degree relatives of breast cancer patients: screening practices and provision of risk information. Cancer Detect Prev 1991; 15(5):379-384.
20. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994; 12:843-850.
21. Kash KM, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992; 84(1):24-30.
22. Winer EP, Winer N, Bluman L, Schildkraut J, Rimer BK. Attitudes and risk perceptions of women with breast cancer considering testing fror BRCA1/2. In Proceeding of the Thirty-third Annual Meeting of ASCO, 537. ASCO, 1997.
23. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997; 89:9-20.
24. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Gen 1998; 62:145-158.
25. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q12. Science 1990; 250:1684-1689.
26. Claus EB, Risch N, Thompson WD. Age of onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990; 131:961-972.
27. Claus EB, Risch N, Thompson WD. Using age of onset to distinguish between subforms of breast cancer. Ann Hum Genet 1990; 54:169-177.
28. Narod SA, Feunteun J, Lynch HT, et al. Familial beast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991; 338:82-83.
29. Murphy EA, Mutalik GS. The application of Bayesian methods in genetic counseling. Hum Heredity 1969; 19:126-151.
30. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston, Butterworth and Heinemann, 1988.
31. Szolovits P, Pauker S. Pedigree analysis for genetic counseling. In: Lun KC et al., eds. MEDINFO-92 Proceedings of the Seventh Conference on Medical Informatics. New York, Elsevier 1992; 679-683.
32. Offit K, Brown K. Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol 1994; 12:1724-1736.
33. Pauker SG, Pauker SP. Prescriptive models to support decision making in genetics. Birth Defects 1987; 23(2):279-296.
34. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56:265-271.
35. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi jews. N Engl J Med 1997; 336:1401.
36. Lange K. Approximate confidence intervals for risk prediction in genetic counseling. Am J Hum Genet 1986; 38(5):681-687.
37. Leal SM, Ott J. Variability of genotype-specific penetrance probabilities in the calculation of risk support intervals. Genet Epidemiol 1995; 12:859-862.
38. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. Cancer 1994; 73:643-651.
39. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Project- ing individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-1886.
40. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene implications for presymptomatic testing and screening. JAMA 1995; 273:535-541.
41. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336:1409-1415.
42. Tengs TO, Winer EP, Paddock S, Aguilar O, Berry DA. Testing for the BRCA1 breast-ovarian cancer susceptibility gene: A decision analysis. Discussion paper, Institute of Statistics and Decision Sciences, 1997.
43. Schrag D, Kuntz K, Garber J, Weeks J. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465-1471.